Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea 131030
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.